Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis
Open Access
- 13 July 2010
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1), 207
- https://doi.org/10.1186/1471-2334-10-207
Abstract
Crimean-Congo hemorrhagic fever epidemics often occur in areas where health services are limited, and result in high case fatality rates. Besides intensive care, ribavirin is often recommended. A solid evidence base for the use of this drug will help justify assuring access to the drug in areas where epidemics are common.Keywords
This publication has 52 references indexed in Scilit:
- The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promisingEuropean Journal of Clinical Microbiology & Infectious Diseases, 2009
- Effectiveness of second generation antipsychotics: A systematic review of randomized trialsBMC Psychiatry, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Uncertainty in heterogeneity estimates in meta-analysesBMJ, 2007
- Imported Crimean-Congo hemorrhagic fever cases in IstanbulBMC Infectious Diseases, 2007
- Crimean–Congo hemorrhagic feverAntiviral Research, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Ebola virus: from discovery to vaccineNature Reviews Immunology, 2003
- Investigation of tick-borne viruses as pathogens of humans in South Africa and evidence of Dugbe virus infection in a patient with prolonged thrombocytopeniaEpidemiology and Infection, 1996
- CRIMEAN-CONGO HAEMORRHAGIC FEVER AND RIFT VALLEY FEVER IN SOUTH-EASTERN MAURITANIAThe Lancet, 1985